Key result
Folic acid (10 mg/d) prevented the development of nitrate tolerance in arteries but had no effect in veins in healthy male volunteers receiving transdermal nitroglycerin.
Why the study?
Does oral supplemental folic acid prevent the development of nitrate tolerance in healthy male volunteers receiving transdermal nitroglycerin?
RCT (n=24)
Does oral supplemental folic acid prevent the development of nitrate tolerance in healthy male volunteers receiving transdermal nitroglycerin?
Oral folic acid supplementation prevents arterial, but not venous, nitrate tolerance during continuous nitroglycerin therapy.
No takes yet. Share an insight, caveat, or question.
Offers a low-cost adjunct to sustain arterial nitroglycerin efficacy; extends mechanistic RCT data toward patient trials.
This study investigated whether oral supplemental folic acid can prevent the development of nitrate tolerance and whether it has different effects on the arterial and venous systems. Twenty-four healthy male volunteers received either placebo or folic acid (10 mg/d) for 14 days. Additionally, all subjects underwent concurrent transdermal nitroglycerin therapy for 7 days. Venous occlusion forearm strain gauge plethysmography measured arterial and venous responses to sublingual nitroglycerin before and after treatment. Both arterial and venous responses were blunted in the placebo group after transdermal nitroglycerin. Folic acid prevented the development of nitrate tolerance in arteries but had no effect in veins.
Gori et al. (2003) conducted an RCT in Healthy volunteers (n=24). Folic acid vs. Placebo was evaluated on Arterial and venous responses to sublingual nitroglycerin. Folic acid (10 mg/d) prevented the development of nitrate tolerance in arteries but had no effect in veins in healthy male volunteers receiving transdermal nitroglycerin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: